For example, a phase I/II study showed that combining Tremelimumab (anti‐CTLA‐4 antibody) with Durvalumab (anti‐PD‐L1 antibody) offered better safety and more durable responses in HCC patients compared with either drug alone.225. Here, CD274 is linked to hepatocellular carcinoma.